The P2Y12 Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y12/Gi-Dependent Mechanism

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Xiang, Binggang ^a   Zhang, Guoying ^a   Ren, Hongmei ^a   Sunkara, Manjula ^a   Morris, Andrew J ^a   Gartner, T Kent ^b   Smyth, Susan S ^a,c   Li, Zhenyu ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF MEMPHIS   (United States)

^c LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYLTHIOADENOSINE 5' MONOPHOSPHATE TRIETHYLAMMONIUM; ADENOSINE TRIPHOSPHATE; CANGRELOR; CYCLIC AMP; FERRIC CHLORIDE; FORSKOLIN; PROSTACYCLIN; PROTEIN KINASE B; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; RAP1 PROTEIN; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CALCIUM MOBILIZATION; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DEFICIENCY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ADENOSINE; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ANIMALS; BLOOD PLATELETS; CELL ADHESION MOLECULES; CYCLIC AMP; EPOPROSTENOL; FORSKOLIN; MICE; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y; SIGNAL TRANSDUCTION; THIONUCLEOSIDES;

MUS;

EID: 84870783907     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051037     Document Type: Article

References (41)

1. Shankar H, Kahner BN, Prabhakar J, Lakhani P, Kim S, et al. (2006) G-protein-gated inwardly rectifying potassium channels regulate ADP-induced cPLA2 activity in platelets through Src family kinases. Blood 108: 3027-3034.
2. Jin J, Daniel JL, Kunapuli SP, (1998) Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 273: 2030-2034.
3. Berridge MJ, (1993) Inositol trisphosphate and calcium signalling. Nature 361: 315-325.
4. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, et al. (2001) Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409: 202-207.
5. Foster CJ, Prosser DM, Agans JM, Zhai Y, Smith MD, et al. (2001) Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 107: 1591-1598.
6. Ohlmann P, Laugwitz KL, Nurnberg B, Spicher K, Schultz G, et al. (1995) The human platelet ADP receptor activates Gi2 proteins. Biochem J 312 (Pt 3): 775-779.
7. Jantzen HM, Milstone DS, Gousset L, Conley PB, Mortensen RM, (2001) Impaired activation of murine platelets lacking G alpha(i2). J Clin Invest 108: 477-483.
8. Andre P, Delaney SM, LaRocca T, Vincent D, DeGuzman F, et al. (2003) P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries. J Clin Invest 112: 398-406.
9. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM, (1992) Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 80: 2787-2796.
10. Dorsam RT, Kunapuli SP, (2004) Central role of the P2Y12 receptor in platelet activation. J Clin Invest 113: 340-345.
11. Committee CS (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348: 1329-1339.
12. Steg PG, James S, Harrington RA, Ardissino D, Becker RC, et al. (2010) Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 122: 2131-2141.
13. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, et al. (2009) G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol 29: 449-457.
14. Damman P, Woudstra P, Kuijt WJ, de Winter RJ, James SK, (2012) P2Y12 platelet inhibition in clinical practice. J Thromb Thrombolysis 33: 143-153.
15. Paul BZ, Jin J, Kunapuli SP, (1999) Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors. J Biol Chem 274: 29108-29114.
16. Kunapuli SP, Ding Z, Dorsam RT, Kim S, Murugappan S, et al. (2003) ADP receptors-targets for developing antithrombotic agents. Curr Pharm Des 9: 2303-2316.
17. Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, et al. (2002) Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 99: 3629-3636.
18. Storey RF, Newby LJ, Heptinstall S, (2001) Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets 12: 443-447.
19. Srinivasan S, Mir F, Huang JS, Khasawneh FT, Lam SC, et al. (2009) The P2Y12 antagonists, 2-methylthioadenosine 5′-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem 284: 16108-16117.
20. Xiang B, Zhang G, Liu J, Morris AJ, Smyth SS, et al. (2010) A G(i)-independent mechanism mediating Akt phosphorylation in platelets. J Thromb Haemost 8: 2032-2041.
21. Au JL, Su MH, Wientjes MG, (1989) Extraction of intracellular nucleosides and nucleotides with acetonitrile. Clin Chem 35: 48-51.
22. Zhang G, Xiang B, Ye S, Chrzanowska-Wodnicka M, Morris AJ, et al. (2011) Distinct Roles for Rap1b Protein in Platelet Secretion and Integrin alphaIIbbeta3 Outside-in Signaling. J Biol Chem 286: 39466-39477.
23. Zhang G, Xiang B, Dong A, Skoda RC, Daugherty A, et al. (2011) Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood 118: 3670-3679.
24. Eigenthaler M, Nolte C, Halbrugge M, Walter U, (1992) Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets. Estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem 205: 471-481.
25. Butt E, Abel K, Krieger M, Palm D, Hoppe V, et al. (1994) cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem 269: 14509-14517.
26. Hauser W, Knobeloch KP, Eigenthaler M, Gambaryan S, Krenn V, et al. (1999) Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci U S A 96: 8120-8125.
27. Chrzanowska-Wodnicka M, Smyth SS, Schoenwaelder SM, Fischer TH, White GC, 2nd (2005) Rap1b is required for normal platelet function and hemostasis in mice. J Clin Invest 115: 680-687.
28. Cifuni SM, Wagner DD, Bergmeier W, (2008) CalDAG-GEFI and protein kinase C represent alternative pathways leading to activation of integrin alphaIIbbeta3 in platelets. Blood 112: 1696-1703.
29. Woulfe D, Jiang H, Mortensen R, Yang J, Brass LF, (2002) Activation of Rap1B by G(i) family members in platelets. J Biol Chem 277: 23382-23390.
30. Lova P, Paganini S, Sinigaglia F, Balduini C, Torti M, (2002) A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets. J Biol Chem 277: 12009-12015.
31. Larson MK, Chen H, Kahn ML, Taylor AM, Fabre JE, et al. (2003) Identification of P2Y12-dependent and-independent mechanisms of glycoprotein VI-mediated Rap1 activation in platelets. Blood 101: 1409-1415.
32. Faxon DP, (2010) Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials. Nat Rev Cardiol 7: 124-125.
33. Angiolillo DJ, Firstenberg MS, Price MJ, Tummala PE, Hutyra M, et al. (2012) Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307: 265-274.
34. Kim S, Mangin P, Dangelmaier C, Lillian R, Jackson SP, et al. (2009) The role of PI 3-K{beta} in glycoprotein VI-mediated akt activation in platelets. J Biol Chem 284: 33763-33772.
35. Lova P, (2004) Campus F, Lombardi R, Cattaneo M, Sinigaglia F, et al (2004) Contribution of protease-activated receptors 1 and 4 and glycoprotein Ib-IX-V in the G(i)-independent activation of platelet Rap1B by thrombin. J Biol Chem 279: 25299-25306.
36. Maloney SF, Brass LF, Diamond SL, (2010) P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. Integr Biol (Camb) 2: 183-192.
37. Johnston-Cox HA, Yang D, Ravid K, (2011) Physiological implications of adenosine receptor-mediated platelet aggregation. J Cell Physiol 226: 46-51.
38. Bodnar RJ, Xi X, Li Z, Berndt MC, Du X, (2002) Regulation of glycoprotein Ib-IX-von Willebrand factor interaction by cAMP-dependent protein kinase-mediated phosphorylation at Ser 166 of glycoprotein Ib(beta). J Biol Chem 277: 47080-47087.
39. Liu M, Simon MI, (1996) Regulation by cAMP-dependent protein kinease of a G-protein-mediated phospholipase C. Nature. 382: 83-87.
40. Woulfe DS, (2010) Akt signaling in platelets and thrombosis. Expert Rev Hematol 3: 81-91.
41. Liu J, Joglekar M, Ware J, Fitzgerald ME, Lowell CA, et al. (2008) Evaluation of the physiological significance of botrocetin/von Willebrand factor in vitro signaling. J Thromb Haemost 6: 1915-1922.